Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Hasn’t Sparked CURE ID Physician Social Network Interest

Executive Summary

US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.

You may also be interested in...



CURE ID Expands Into COVID-19; Oncology And Rare Diseases Are Next

After slow start early in SARS-CoV-2 pandemic, CURE ID now has more than 150 case reports of drugs to treat the coronavirus.

Real-World Evidence On COVID-19: US FDA Approaching With 'Sense Of Urgency'

Agency is going outside its ‘comfort zone’ to leverage different streams of existing real-world data sources to quickly assess the impact of potential treatment approaches, Amy Abernethy says; pandemic experience could lead to a more open embrace of RWE beyond the current public health emergency.

AnGes Takes DNA Vaccine Tack As It Enters Virus R&D Fray

Japanese bioventure goes down the DNA vaccine route, along with several others worldwide, pointing to potential development speed and safety advantages.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel